Metabolic, Circadian trading halted ahead of trial results

By Staff Writers
Thursday, 09 December, 2004

Trading in shares of Metabolic Pharmaceuticals (ASX:MBP) and Circadian Technologies (ASX:CIR) was halted today, in advance of the release of data from Phase IIb trials of Metabolic's obesity drug, AOD9604.

Circadian is Metabolic's largest shareholder, owning 21 per cent of shares.

'Low-risk' antibiotic linked to rise of dangerous superbug

A new study has challenged the long-held belief that rifaximin — commonly prescribed to...

Robotic hand helps cultivate baby corals for reef restoration

The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...

Stem cell experiments conducted in space

Scientists are one step closer to manufacturing stem cells in space — which could speed up...

Content from other channels on our network

CSIRO electrolyser pilot a success at Bluescope Steel

Three states announce BESS projects in a week

Emerson offers solution to reduce energy costs and emissions

CSIRO solar venture nets record seed funding

Rockwell Automation and Microsoft expand cloud and AI partnership

Rising healthcare facility demands pave way for innovation

Designs unveiled for the new Melton Hospital

AIA Australia launches virtual mental health service

Depressive disorders: 70% of Australians not getting adequate treatment

High blood pressure costs Australia $1.2bn a year

Making Australian canola oil more sustainable with solar power

Who will pay for emission reductions in the milk sector?

Fonterra charts progress against its 'Climate Roadmap'

How to manage safety risks in the low-moisture food sector?

Pure Dairy appoints new CCO